Third, the nanoplatelets were removed exclusively by the liver and spleen, and the transferrin-coupled nanoplatelets had a stronger tumor-targeting effect than the control nanoplatelets without transferrin (Supplementary Figure S1). This evidence concerns the gene TF and neoplasm.